Compare Gilead Sciences, Inc. (GILD) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs W W Grainger Inc — how do they compare? Gilead Sciences, Inc. trades at $136.19 (market cap $168.35B), while W W Grainger Inc trades at $1,309.66 (market cap $61.32B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× W W Grainger Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | GWW | |
|---|---|---|
Market Cap | $168.35B | $61.32B |
Sector | Health | Technology |
52-Week High | $155.80 | $1.40K |
52-Week Low | $110.56 | $918.18 |
Enterprise Value | $191.42B | $63.53B |
Dividend Yield | 2.42% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
W.W. Grainger (GWW) trades at $1,299.53, showing modest daily gains of 0.16%. The stock demonstrates strong fundamental performance with Q2 2026 earnings beating estimates at $12.01 per share versus $11.30 expected, and revenue reaching $5 billion. Technical indicators show bearish momentum with the current price between support at $1,282 and resistance at $1,305. The company raised its full-year 2026 outlook following strong quarterly results driven by margin expansion and market share gains.
GWW presents a mixed investment case with strong profitability metrics (ROE 47.92%, net margin 9.92%) offset by premium valuation (P/E 33.19). Analyst consensus leans cautious with 65.79% hold ratings despite recent earnings beats. Key risks include valuation concerns and competitive pressures in industrial distribution. The $1,320 consensus price target suggests limited upside from current levels, requiring careful monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
